DEPARTMENT OF HUMAN SERVICES

Meeting Minutes: Drug Formulary Committee - DRAFT

Date and Time:	July 17, 2024; 9:15 a.m. – 1:30 p.m. (Central Time)
Minutes prepared by:	Naana Osei-Boateng and Dave Hoang
Location:	Virtual Meeting via Zoom or In-person Meeting at Elmer Andersen Building, Room 2370

Attendance

- Members in attendance: Amirala Pasha, DO, JD; Mary Mescher Benbenek, PhD, APRN; Jacques Beasley; Arthur Beisang, MD; Emily Jaeger, PharmD; Kathryn Lombardo, MD; Kelly Ruby, PharmD; Sheila Scheuer, PharmD; Sofia Shrestha, PharmD; Sandra Widhalm Murphy, RPh; Jena Wirt, DO; Julie Wolfgram, DNP, FNP
- Members absent: Margaret Artz, RPh, PhD; Stuart Williams, JD; Monica Brands, RPh; Katherine Montag Schafer, PharmD; James Phillips, MD
- DHS staff present: Dave Hoang, PharmD, MBA; Nathan Chomilo, MD; Aaron Drake, RPh
- Others in attendance: Julie McKee, PharmD; Chloe Groomes, PharmD; Naana Osei-Boateng, PharmD; Joshua Williams, PharmD

Report of the Chair

- Kelly Ruby presided over the meeting.

Approval of Minutes

- The committee reviewed and accepted the Minutes from the April 2024 meeting.

DHS Housekeeping

- Dave Hoang introduced and welcomed DFC member Amirala Pasha, DO, JD, to his first DFC meeting.

Old Business

- None

New Business

Existing Specialty Drugs for Continued PA

The DFC reviewed and unanimously voted to approve the Synagis PA criteria. There were no changes to the policy for this season.

Specialty Drugs for Continued Prior Authorization (PA)

- The committee discussed Agamree and recommended to DHS by a unanimous vote that Agamree remain on PA with the proposed criteria.

- The committee discussed Zilbrysq and recommended to DHS by a unanimous vote that Zilbrysq remain on PA with the following amendment to the proposed criteria:
    - Original bullet point # 13 under initial approval criteria (*Zilbrysq is prescribed by or in consultation with a neurologist.)* amended to become bullet # 7 under initial approval criteria

- The committee discussed Fabhalta and recommended to DHS by a unanimous vote that Fabhalta remain on PA with the following amendments to the proposed criteria
    - Bullet point # 6 under initial approval criteria amended to read: Patient does not have an unresolved infection and if infection by an unencapsulated bacteria occurs, the medication will be stopped
    - Bullet point # 14 under initial approval criteria amended to read: Prescriber will monitor for signs of hemolysis <u>for a minimum of 2 weeks</u> after Fabhalta discontinuation
    - Insertion of bullet point # 15 under initial approval criteria to read: <u>Prescriber must be registered with the Fabhalta REMS program.</u>
    - *Initial approval is for 6 months* will now become bullet point #16

- The committee discussed Eohilia and recommended to DHS by a unanimous vote that Eohilia remain on PA with the following amendment to the proposed criteria:
    - Bullet point # 2 under initial approval criteria amended to read: Eohilia is prescribed by <u>or in consultation with</u> a gastroenterologist, allergist or immunologist

- The committee discussed Wainua and recommended to DHS by a unanimous vote that Wainua remain on PA with the proposed criteria.

- The committee discussed Rivfloza and recommended to DHS by a majority vote that Rivfloza remain on PA with the following amendment to the proposed criteria:
    - Bullet point # 3 under initial approval criteria amended to read: <u>To monitor for response, patient has a baseline measurement of one or more</u> of the following…

- The committee discussed Filsuvez and recommended to DHS by a unanimous vote that Filsuvez remain on PA with the proposed criteria.

Preferred Drug List (PDL) Review

- The committee discussed the Anticonvulsants, Other therapeutic class and recommended the following to the department by a unanimous vote:
    - LIBERVANT (BUCCAL) to be added to the PDL as NONPREFERRED
    - DIASTAT (RECTAL) to be removed from the PDL as it is no longer on the market.
- The committee discussed the Antiemetic/Antivertigo Agents therapeutic class and recommended the following to the department by a unanimous vote:
    - DICLEGIS (ORAL) to be added to the PDL as PREFERRED
    - BONJESTA (ORAL) and DOXYLAMINE SUCCINATE/VIT B6 (DICLEGIS) (ORAL) to be added to the PDL as NONPREFERRED
- The committee discussed the Antifungals, Topical therapeutic class and recommended the following to the department by a unanimous vote:
    - ERTACZO (TOPICAL), OXISTAT LOTION (TOPICAL) to be added to the PDL as NONPREFERRED
    - BENSAL HP (TOPICAL), EXELDERM CREAM (TOPICAL), EXELDERM SOLUTION (TOPICAL), NAFTIFINE CREAM (TOPICAL). OXISTAT CREAM (TOPICAL), PENLAC (TOPICAL). SULCONAZOLE NITRATE CREAM (TOPICAL), SULCONAZOLE NITRATE SOLUTION (TOPICAL) to be removed from the PDL.
- The committee discussed the Antimigraine Agents, Other therapeutic class and recommended the following to the department by a unanimous vote:
    - AIMOVIG (SUBCUTANE.) to be moved to the PDL as PREFERRED.
    - ZAVZPRET (NASAL) to be added to the PDL as NONPREFERRED.
- The committee discussed the Antiparkinson's Agents therapeutic class and recommended the following to the department by a unanimous vote:
    - DHIVY TABLET (ORAL) and TASMAR (ORAL) to be added to the PDL as NONPREFERRED.
    - MIRAPEX (ORAL) and SINEMET CR (ORAL) to be removed from the PDL.
- The committee discussed the Antivirals, Topical therapeutic class and recommended the following to the department by a unanimous vote:
    - PENCICLOVIR (TOPICAL) to be added to the PDL as NONPREFERRED.
- The committee discussed the Calcium Channel Blockers therapeutic class and recommended the following to the department by a unanimous vote:

- ISRADIPINE (ORAL), NICARDIPINE (ORAL), VERAPAMIL 360 MG CAPSULE (ORAL) and VERAPAMIL ER PM (ORAL) to be moved to the PDL as NONPREFERRED.
- DILTIAZEM TABLET ER (LA) (ORAL), KATERZIA (ORAL), LEVAMLODIPINE MALEATE (ORAL) and NORLIQVA (ORAL) to be added to the PDL as NONPREFERRED.
- VERELAN (ORAL) to be removed from the PDL.

- The committee discussed the Glucagon Agents therapeutic class (a new class to the PDL) and recommended the following to the department by a unanimous vote:

  - BAQSIMI (NASAL), GLUCAGON EMERGENCY KIT (AMPHASTAR) (INJECTION) to be added to the PDL as PREFERRED.
  - GLUCAGON EMERGENCY KIT (FRESENIUS) (INJECTION), GVOKE VIAL (SUBCUTANEOUS), GVOKE SYRINGE (SUBCUTANEOUS), GVOKE PEN (SUBCUTANEOUS), ZEGALOGUE SYRINGE (SUBCUTANEOUS) and ZEGALOGUE AUTOINJECTOR (SUBCUTANEOUS) to be added to the PDL as NONPREFERRED.
  - GLUCAGON (LILLY) (INJECTION) to be removed from the PDL.

- The committee discussed the Lipotropics, Statins therapeutic class and recommended the following to the department by a unanimous vote:

  - ATORVALIQ (ORAL) to be added to the PDL as NONPREFERRED.
  - PRAVACHOL (ORAL) to be removed from the PDL.

- The committee discussed the Ophthalmics, Anti-Inflammatory/Immunomodulator therapeutic class (a new class to the PDL) and recommended the following to the department by a unanimous vote:

  - RESTASIS (OPHTHALMIC), RESTASIS MULTIDOSE (OPHTHALMIC) and XIIDRA (OPHTHALMIC) to be added to the PDL as PREFERRED
  - CEQUA (OPHTHALMIC), CYCLOSPORIN (OPHTHALMIC), EYSUVIS (OPHTHALMIC), MIEBO (OPHTHALMIC), TYRVAYA SPRAY (NASAL), VERKAZIA (OPHTHALMIC) and VEVYE (OPHTHALMIC) to be added to the PDL as NONPREFERRED

- The committee discussed the Proton Pump Inhibitors therapeutic class and recommended the following to the department by a unanimous vote:

  - DEXLANSOPRAZOLE CAPSULE (ORAL) and KONVOMEP (ORAL) to be added to the PDL as NONPREFERRED
  - ACIPHEX SPRINKLE (ORAL) to be removed from the PDL.

- The committee discussed the Weight Management Agents therapeutic class and recommended the following to the department by a unanimous vote:

  - ZEPBOUND (SUBCUTANEOUS) to be added to the PDL as NONPREFERRED

CONSENT AGENDA ITEMS:

The committee discussed and recommended by unanimous vote that all classes in the Consent Agenda Items be passed as presented with no changes.

Other Business

- There was discussion of potential for removal of Hepatitis C PA criteria. The class will be presented to the DFC for review at the appropriately scheduled meeting. Interested persons should sign up to receive notifications of upcoming meetings on the DFC website.

Adjournment

- The meeting was adjourned at approximately 11:56 a.m. Central Time.